default author photo

Vanesa Quiroga

Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology

P.O. Box 2046

Barcelona, E-08907

Spain

  • Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology

SCHOLARLY PAPERS

1

DOWNLOADS

61

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour Response

Downloads 61

Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour Response

Number of pages: 32 Posted: 03 Dec 2024
Joanna I. López-Velazco, Sara Manzano, Kepa Elorriaga, Maria Otaño, Ainhara Lahuerta, Luis Álvarez, Inge Etxabe, Miren Huarte, Elvira Buch, Julia Gimenez, Vanesa Quiroga, Marta Fernandez, Sofía Aragón, Laia Paré, Aleix Prat, Isabel Álvarez-López, MARIA CAFFAREL and Ander Urruticoechea
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology, affiliation not provided to SSRN, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Universidad de Barcelona - Hospital Clínic Barcelona, Hospital Clinic of Barcelona - Department of Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 36

Abstract:

Loading...

Neoadjuvant endocrine therapy, aromatase inhibitors, ER+/HER2- breast cancer, PAM50, normal-like subtype, ROR, p53

Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour Response

Number of pages: 32 Posted: 16 Apr 2025
Joanna I. López-Velazco, Sara Manzano, Kepa Elorriaga, Maria Otaño, Ainhara Lahuerta, Luis Álvarez, Inge Etxabe, Miren Huarte, Elvira Buch, Julia Gimenez, Vanesa Quiroga, Marta Fernandez, Sofía Aragón, Laia Paré, Aleix Prat, Isabel Álvarez-López, MARIA CAFFAREL and Ander Urruticoechea
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology, affiliation not provided to SSRN, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Universidad de Barcelona - Hospital Clínic Barcelona, Hospital Clinic of Barcelona - Department of Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 25

Abstract:

Loading...

Neoadjuvant endocrine therapy, Aromatase inhibitors, ER+/HER2- breast cancer, PAM50